Related Experiment Video
Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Drug Development
Aiman Hamli1, Kalavathy Ramasamy2,3, Snezana Agatonovic-Kustrin4,5
1Universiti Teknologi MARA (UiTM), Bandar Puncak Alam, Selangor, Malaysia.
Background:
Current pharmacological therapies against Alzheimer's disease (AD) merely relieve the clinical symptoms but fail to halt the progression of the neurodegenerative disease. This raises the need for alternative neuroprotective agents that can prevent AD. Based on its antioxidant and anti-inflammation properties, the marine alga, Caulerpa lentillifera, appears to be useful against the neuroinflammation-driven AD. As such, this study aimed at uncovering the neuroprotective potential of C. lentillifera extracts against lipopolysaccharide (LPS)-induced neuroinflammation in vitro.
Method:
Briefly, freeze-dried C. lentillifera was extracted using methanol, and partitioned into hexane, chloroform and ethyl acetate. The resultant C. lentillifera extracts [i.e., methanol (CLME], hexane (CLHE), chloroform (CLCE), ethyl acetate (CLEAE)] were evaluated for antioxidant activity (DPPH) and COX-1 inhibition using high-performance thin layer chromatography (HPTLC). The extracts were also tested against LPS-challenged macrophage (RAW 264.7) and neuroblastoma (SK-N-SH) cells. Reactive oxygen species (ROS) production, nitric oxide (NO) levels and caspase-3 activity were measured. Phytochemical profiling was performed using nuclear magnetic resonance (NMR) spectroscopy.
Result:
HPTLC found CLCE to exhibit the highest DPPH scavenging activity but relatively weak COX-1 inhibition. When compared to CLCE, CLHE elicited moderate DPPH scavenging activity but relatively stronger COX-1 inhibition whilst CLEAE exhibited the greatest COX-1 inhibition. For RAW 264.7 cells, CLCE and CLHE were the two most potent extracts that significantly reduced ROS (≥ -36.24%), NO (≥ -43.71%) and caspase-3 activity (≥ -95.26%) in LPS-challenged cells. For SK-N-SH cells, CLCE and CLHE were also the two most potent extracts that significantly reduced ROS (≥ -71.73 %) and Caspase-3 activity (≥ -54.67%) in LPS-challenged cells. Phytochemical profiling of the extracts found CLCE to be presented with the highest phenolic content, followed by CLHE, CLME and CLEAE. NMR spectroscopy analysis revealed that CLME contained sugar and sterols; CLCE contained palmitic acids, polysaccharides and amino acids; CLEAE contained polysaccharides, terpenoids and phenolic compounds; CLHE contained fatty acids and oleic acids.
Conclusion:
C. lentillifera extracts, particularly CLME and CLHE, could potentially confer neuroprotection against neuroinflammation by reducing oxidative stress, inflammation, and apoptosis.
Funding:
Fundamental Research Grant Scheme, Ministry of Higher Education, Malaysia (FRGS/1/2019/STG03/UITM/03/1).
More Related Videos
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
Related Concept Videos
Preclinical Development: Overview
Clinical Trials: Overview
Drug Discovery: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
In Vitro Drug Release Testing: Overview, Development and Validation
Drug Regulation